Gerspach J - Search Results

1

TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor.

Wüest T, Gerlach E, Banerjee D, Gerspach J, Moosmayer D, Pfizenmaier K. Wüest T, et al. Among authors: gerspach j. Oncogene. 2002 Jun 20;21(27):4257-65. doi: 10.1038/sj.onc.1205193. Oncogene. 2002. PMID: 12082613

2

Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted Activation.

Samel D, Muller D, Gerspach J, Assohou-Luty C, Sass G, Tiegs G, Pfizenmaier K, Wajant H. Samel D, et al. Among authors: gerspach j. J Biol Chem. 2003 Aug 22;278(34):32077-82. doi: 10.1074/jbc.M304866200. Epub 2003 May 28. J Biol Chem. 2003. PMID: 12773535 Free article.

3

Tumor therapeutics by design: targeting and activation of death receptors.

Wajant H, Gerspach J, Pfizenmaier K. Wajant H, et al. Among authors: gerspach j. Cytokine Growth Factor Rev. 2005 Feb;16(1):55-76. doi: 10.1016/j.cytogfr.2004.12.001. Cytokine Growth Factor Rev. 2005. PMID: 15733832 Review.

4

Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface.

Gerspach J, Németh J, Münkel S, Wajant H, Pfizenmaier K. Gerspach J, et al. Cancer Immunol Immunother. 2006 Dec;55(12):1590-600. doi: 10.1007/s00262-006-0162-6. Epub 2006 Apr 25. Cancer Immunol Immunother. 2006. PMID: 16636812

5

Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity.

Krippner-Heidenreich A, Grunwald I, Zimmermann G, Kühnle M, Gerspach J, Sterns T, Shnyder SD, Gill JH, Männel DN, Pfizenmaier K, Scheurich P. Krippner-Heidenreich A, et al. Among authors: gerspach j. J Immunol. 2008 Jun 15;180(12):8176-83. doi: 10.4049/jimmunol.180.12.8176. J Immunol. 2008. PMID: 18523283

6

Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands.

Gerspach J, Wajant H, Pfizenmaier K. Gerspach J, et al. Results Probl Cell Differ. 2009;49:241-73. doi: 10.1007/400_2008_22. Results Probl Cell Differ. 2009. PMID: 19142623 Review.

7

Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects.

Gerspach J, Pfizenmaier K, Wajant H. Gerspach J, et al. Biofactors. 2009 Jul-Aug;35(4):364-72. doi: 10.1002/biof.50. Biofactors. 2009. PMID: 19484741 Review.

8

Therapeutic targeting of CD95 and the TRAIL death receptors.

Gerspach J, Pfizenmaier K, Wajant H. Gerspach J, et al. Recent Pat Anticancer Drug Discov. 2011 Sep;6(3):294-310. doi: 10.2174/157489211796957739. Recent Pat Anticancer Drug Discov. 2011. PMID: 21762072 Review.

9

Genetic engineering of death ligands for improvement of therapeutic activity.

Gerspach J, Schneider B, Müller N, Otz T, Wajant H, Pfizenmaier K. Gerspach J, et al. Adv Exp Med Biol. 2011;691:507-19. doi: 10.1007/978-1-4419-6612-4_53. Adv Exp Med Biol. 2011. PMID: 21153356 No abstract available.

10

Engineering death receptor ligands for cancer therapy.

Wajant H, Gerspach J, Pfizenmaier K. Wajant H, et al. Among authors: gerspach j. Cancer Lett. 2013 May 28;332(2):163-74. doi: 10.1016/j.canlet.2010.12.019. Epub 2011 Jan 14. Cancer Lett. 2013. PMID: 21236560 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

24 results

Search Page